# Safety and Efficacy of HPP737 in Adult Patients With Plaque Psoriasis

> **NCT07707141** · PHASE2 · COMPLETED · sponsor: **Newsoara Biopharma Co., Ltd.** · enrollment: 123 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** HPP737 6mg and placebo
- **DRUG:** HPP737 10mg and placebo
- **DRUG:** HPP737 20mg
- **DRUG:** HPP737 placebo

## Key facts

- **NCT ID:** NCT07707141
- **Lead sponsor:** Newsoara Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-03
- **Primary completion:** 2021-12-20
- **Final completion:** 2021-12-20
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07707141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07707141, "Safety and Efficacy of HPP737 in Adult Patients With Plaque Psoriasis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07707141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*